{"doi":"10.1002/mdc3.13754","title":"A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease","abstract":"Background: Pain is common in Parkinson's disease (PD), but effective therapies are limited. Objectives: To determine the maximum tolerated dose (MTD) and safety of formulations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for pain in PD. Methods: In this phase 1b, double-blind, randomized, single-center study, participants were randomized to three formulations of THC/CBD (18:0, 10:10, and 1:20). The MTD, adverse events (AE), and tolerability are described for each formulation. Results: Eight participants were randomized. The MTD was similar among groups (0.8-0.9 mL/daily), and there were no serious AE or study drop-outs. The most common AE were drowsiness and dizziness (three participants). Epworth sleepiness scale scores were higher in the high CBD formulation (1:20). Conclusions: In patients with pain and PD, mixed formulations of THC/CBD were tolerated with no serious AE. Considering the safety profile, future phase II studies should be considered.","journal":"Movement Disorders Clinical Practice","year":2023,"id":351059,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9505,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1095779,"name":"Gabriela S. Gilmour","orcid":"0000-0002-9301-8423","position":1,"is_corresponding":false},{"id":779632,"name":"Conor Fearon","orcid":"0000-0002-8172-6094","position":2,"is_corresponding":false},{"id":1095780,"name":"Emily Swinkin","orcid":"0000-0002-5208-7203","position":3,"is_corresponding":false},{"id":1095781,"name":"Maria Eliza Freitas","orcid":"0000-0003-3315-0892","position":4,"is_corresponding":false},{"id":1096245,"name":"G. Kuhlman","orcid":null,"position":5,"is_corresponding":false},{"id":245790,"name":"Susan H. Fox","orcid":"0009-0004-7568-1645","position":6,"is_corresponding":false},{"id":523733,"name":"Tiago Mestre","orcid":"0000-0002-6973-7479","position":7,"is_corresponding":false},{"id":1095778,"name":"Daniel G. Di Luca","orcid":"0000-0002-1356-4919","position":0,"is_corresponding":true}],"reference_count":20,"raw_metadata":null,"created_at":"2026-07-19T01:12:41.740237Z","pmid":"37476317","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}